News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study

22 June 2023

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress

30 March 2023

Invitation to investor meeting 5th April 2023, 2:00 pm (CET)

28 March 2023

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer

8 March 2023

Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio Copy

23 January 2023

R&D Day Presentation, 07.12.2022

7 December 2022

Events & Presentations

ESMO – 8-12 September 2017 Madrid

1 September 2017

ERS – 9-13 September 2017 Milan

1 September 2017

BIO USA – San Diego 19-22 June 2017

1 June 2017

ATS – Washington 19-24 May 2017

1 May 2017
This site is registered on wpml.org as a development site.